论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
NLRP3 炎性体作为治疗心脏纤维化的新靶点
Authors Fan J, Ren M, Adhikari BK , Wang H, He Y
Received 12 April 2022
Accepted for publication 1 July 2022
Published 7 July 2022 Volume 2022:15 Pages 3847—3858
DOI https://doi.org/10.2147/JIR.S370483
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Ning Quan
Abstract: Cardiac fibrosis often has adverse cardiovascular effects, including heart failure, sudden death, and malignant arrhythmias. However, there is no targeted therapy for cardiac fibrosis. Inflammation is known to play a crucial role in the disorder, and the NLR pyrin domain-containing-3 (NLRP3) inflammasome is closely associated with innate immunity. Therefore, further understanding the pathophysiological role of the inflammasome in cardiac fibrosis may provide novel strategies for the prevention and treatment of the disorder. The aim of this review was to summarize the present knowledge of NLRP3 inflammasome-related mechanisms underlying cardiac fibrosis and to suggest potential targeted therapy that could be used to treat the condition.
Keywords: NLRP3 inflammasome, cardiac fibrosis, AIM2, ASC, caspase-1